Second COVID-19 vaccine set to be authorized in US with panel endorsement
WASHINGTON (AP) A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
The Food and Drug Administration is expected to follow the recommendation for the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0 vote, agreed the benefits of the vaccine outweighed the risks for those 18 years old and up.
The FDA’s green light for emergency use is expected quickly. Moderna would then begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.
Expert panel votes FDA SHOULD give Moderna s COVID-19 vaccine emergency approval amid hopes the U.S will soon have a second shot to help get 20 million Americans vaccinated by the end of 2020
A panel of FDA experts voted that the agency should approve Moderna s coronavirus vaccine and recommend whether the shot should be approved
With their endorsement, Moderna s shot will almost certainly get emergency approval tonight or tomorrow
Two people in Moderna s trial had severe allergic reactions: one who got a placebo, and a vaccine recipient who had anaphylactic shock 63 days later
Moderna determined neither were linked to the shot, and allergic reactions are generally immediate, not months later
FDA advisers recommend 2nd coronavirus vaccine, with agency approval expected soon Published December 17, 2020
Share on Facebook
Print article WASHINGTON The head of the Food and Drug Administration said late Thursday that his agency will move to quickly authorize the second COVID-19 vaccine to fight the pandemic, hours after the shot won the key endorsement of a government advisory panel. FDA Commissioner Stephen Hahn said in a statement that regulators have communicated their plans to drugmaker Moderna, which co-developed the vaccine with the National Institutes of Health. The announcement came after a panel of FDA advisers, in a 20-0 vote, ruled that the benefits of the vaccine outweighed the risks for those 18 years old and up.
Moderna COVID-19 vaccine gets endorsement from U.S. government advisory panel
Published
A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
The Food and Drug Administration is expected to follow the recommendation for the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0 vote, agreed the benefits of the vaccine outweighed the risks for those 18 years old and up.
The FDA s green light for emergency use is expected quickly. Moderna would then begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.
FDA advisory panel votes to recommend approval of Moderna’s COVID-19 vaccine
FDA does not have to follow the advice of the panel
Updated:
Tags:
FILE - A man stands outside an entrance to a Moderna, Inc., building, Monday, May 18, 2020, in Cambridge, Mass. A second COVID-19 vaccine moved closer to joining the U.S. fight against the pandemic Thursday, Dec. 17, 2020 as government experts convened for a final public review of its safety and effectiveness. The shot from Moderna and the National Institutes of Health is urgently needed as the country continues to record ever-higher numbers of new cases, hospitalizations and deaths ahead of more holiday travel and family gatherings. FDA s OK is expected shortly after the all-day meeting concludes. (AP Photo/Bill Sikes, file) (Copyright 2020 The Associated Press. All rights reserved)